Search - tctmd.com

Displaying 1 - 20 of 58

Sort: Relevancy | Date

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Oxygen of No Benefit, Even in MI Patients With Low-Normal Saturation

Michael O'Riordan

December 16, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

SILVER-AMI Bests GRACE for Predicting 6-Month Mortality After Acute MI in Elderly

L.A. McKeown

December 10, 2019

News Daily News

Physicians as Patients: Better Health, Less CV Prevention Among Ontario Doctors Than General Public

Yael L. Maxwell

November 26, 2019

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Todd Neale

November 20, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Bulimia May Contribute to Premature CVD in Women

L.A. McKeown

October 18, 2019

News Daily News

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Caitlin E. Cox

October 02, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

Advertisement

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Oxygen of No Benefit, Even in MI Patients With Low-Normal Saturation

FDA Approves Icosapent Ethyl for Reducing CVD Events

SILVER-AMI Bests GRACE for Predicting 6-Month Mortality After Acute MI in Elderly

Physicians as Patients: Better Health, Less CV Prevention Among Ontario Doctors Than General Public

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Bulimia May Contribute to Premature CVD in Women

Drug Abuse in Infective Endocarditis Patients Spikes Amid US Opioid Epidemic

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content